

Format for Disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011


Name of the Target Company (TC)	Glenmark Pharmaceuticals Ltd.		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	OppenheimerFunds, Inc. (F.I.I.)		
Whether the acquirer belongs to Promoter/Promoter group	No		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	National Stock Exchange of India Bombay Stock Exchange		
Details of the acquisition / disposal as follows	Number	% w.r.t. total share/voting capital wherever applicable(*)	% w.r.t. total diluted share/voting capital of the TC (**)
Before the acquisition / sale under consideration, holding of:			
a) Shares carrying voting rights	14,059,727	4.98%	4.98%
b) Shares in the nature of encumbrance (pledge/ lien/non-disposal undertaking/ others)			
c) Voting rights (VR) otherwise than by equity shares			
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)			
e) Total (a+b+c+d)	14,059,727	4.98%	4.98%
Details of acquisition / sale			
a) Shares carrying voting rights acquired / sold	74,647	0.03%	0.03%
b) VRs acquired / sold otherwise than by equity shares			
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired / sold			
d) Shares encumbered / invoked/released by the acquirer			
e) Total (a+b+c+/-d)	74,647	0.03%	0.03%

6/2/2014
130696

After the acquisition/sale, holding of:	14,134,374	5.01%	5.01%
a) Shares carrying voting rights			
b) Shares encumbered with the acquirer			
c) VRs otherwise than by shares			
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition			
e) Total (a+b+c+d)	14,134,374	5.01%	5.01%
Mode of acquisition / sale (e.g. open market / off-market / public issue / rights issue / preferential allotment / inter-se transfer etc).	Open market		
Date of acquisition / sale of shares / VR or date of receipt of intimation of allotment of shares, whichever is applicable	January 31, 2017		
Equity share capital / total voting capital of the TC before the said acquisition / sale	282,168,156		
Equity share capital/ total voting capital of the TC after the said acquisition / sale	282,168,156		
Total diluted share/voting capital of the TC after the said acquisition / sale	282,168,156		

(*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.



Signature of the acquirer / seller / Authorized Signatory

Place: 225 Liberty Street, New York, NY 10281 USA

Date: February 2, 2017